Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
In light of publication from
Thouvenot et al in JAMA
Related Questions
How do you counsel women on anti-CD20 therapy for MS who are planning for pregnancy?
How do you handle medication management for patients on immunosuppressive therapy who are lost to follow-up?
How does your decision to use high-efficacy disease-modifying treatments (HET) differ, if at all, when treating late-onset relapsing-remitting multiple sclerosis?
What are your vaccine recommendations while patients are on biologics?
Do you have any clinical experience regarding the administration of B cell depleting therapies in MS patients with splenectomy?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
What biomarkers best predict the response to B-cell depleting therapies in MS?
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
How can we minimize the risk of overinterpreting reactive findings from repeat lumbar punctures?
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?